 STUDY TO EVALUATE SAFETY, TOLERABILITY, MAXIMUM TOLERATED DOSE MTD, EFFICACY, AND PHARMACOKINETICS PKS OF CPI-613 GIVEN TWICE WEEKLY FOR THREE CONSECUTIVE WEEKS IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES: 